Natural moisturizing factor as a clinical marker in atopic dermatitis by Nouwen, A.E.M. (Anouk E. M.) et al.
Allergy. 2019;00:1–3.	 wileyonlinelibrary.com/journal/all	 	 | 	1© 2019 EAACI and John Wiley and Sons A/S. 
Published by John Wiley and Sons Ltd.
 
DOI: 10.1111/all.13942  
L E T T E R  T O  T H E  E D I T O R
Natural moisturizing factor as a clinical marker in atopic 
dermatitis
To the Editor
Atopic dermatitis (AD) is a heterogeneous disease with various 
biological origins and clinical appearances. It is likely that different 
therapies or treatment intensities are not equally effective for all AD 
endotypes. The strongest genetic risk factor for AD is a null muta‐
tion in the filaggrin gene (FLG).1 Patients with eczema who carry a 
FLG null mutation are also prone to more persistent, severe eczema, 
and earlier onset of AD compared to patients without a FLG null 
mutation.
Stratification of patients based on the FLG null endotype could 
enable more targeted treatment. Methods to determine FLG null 
mutations based on genotyping are time consuming and require 
specialized laboratory infrastructure, further complicated by the 
existence of over 50 different polymorphisms with widely varying 
prevalences between ethnic groups.2 In the stratum corneum (SC) 
filaggrin is enzymatically degraded into its constituting amino acids 
and their derivatives, together with specific salts and sugars collec‐
tively named natural moisturizing factor (NMF). Decreased NMF 
provides an accurate surrogate marker for the presence of FLG null 
polymorphisms.3 This can be measured rapidly and noninvasively by 
Raman spectroscopy in a clinically compatible test.
We have assessed the potential of NMF as a novel clinical marker 
in AD by examining the association of clinically measured NMF val‐
ues with severity of AD, early onset of AD, and the co‐morbidities 
of AD: allergic sensitization, food allergy, bronchial hyperreactivity 
(BHR), asthma, and allergic rhinitis.
Of 207 children with AD (0‐18 years of age), NMF values had 
been measured routinely during a visit to the pediatric atopy cen‐
ter KinderHaven‐Sophia Children's Hospital‐Erasmus MC University 
Medical Center Rotterdam in The Netherlands. The retrospective 
study protocol was approved by the medical ethics committee of 
Erasmus MC (MEC‐2016‐244). AD was diagnosed by a dermatologist 
according to the UK Working Party's Diagnostic Criteria for Atopic 
Dermatitis.4 NMF had been measured noninvasively on the palm of 
the hand by Raman spectroscopy using an in vivo Raman skin ana‐
lyzer (gen2‐SCA, RiverD International BV, Rotterdam). NMF values 
were classified as normal NMF (>1.14 arbitrary units) or decreased 
NMF (<0.995 arbitrary units), using a 0.07 confidence interval around 
the threshold of 1.07 as established by O’Regan et al.3 Patients with 
a NMF value between 0.995‐1.14 were excluded. The interval was 
the estimated 95% confidence interval, calculated as the standard 
error (SE) of the NMF value, averaged over the entire cohort, and 
multiplied by 1.96. Disease characteristics and comorbidity status 
were retrieved from the electronic medical patient files by two in‐
dependent researchers (see Appendix S1). Severity (mild to moderate 
or severe) of AD was measured by proxy of therapy based on the cri‐
teria as described by Wollenberg et al5 (Appendix S1). Associations 
between NMF status and the clinical parameters were tested by uni‐
variate and multivariate logistic regression models with adjustment 
for age and gender.
Sixty‐seven out of 207 (32.4%) patients had decreased NMF. 
Figure 1 shows the distribution of disease severity in relation to the 
groups normal NMF and decreased NMF. Patients with decreased 
NMF had increased risk of severe AD, OR 2.12 (95% CI 1.02‐4.43), 
sensitization for food allergens, OR 2.27 (95%CI 1.21‐4.23), sensiti‐
zation for inhalation allergens, OR 2.22 (95%CI 1.13‐4.34), and food 
allergies, OR 2.79 (95% CI 1.33‐5.86; Table 1 and Table S1). Having 
decreased NMF did not show an association with early‐onset AD, 
allergic rhinitis, BHR, asthma and combined asthma, and/or BHR.
In this retrospective study, we examined the associations between 
NMF values and the clinical parameters of the atopic syndrome. NMF 
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F I G U R E  1   Distribution of disease severity and NMF status 
(n = 207). Black: mild to moderate AD; White: severe AD. The 
percentage of patients with severe AD is significantly higher in the 
decreased NMF group then in the normal NMF group (P < 0.05 
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values had been measured rapidly and noninvasively by Raman spec‐
troscopy. The results show a strong association between AD disease 
severity based on prior therapy, and NMF value. Decreased NMF 
also shows associations with the co‐morbidities allergic sensitization 
for food and inhalant allergens and food allergy. These findings are 
in concordance with the reported and widely replicated associations 
between FLG null mutations and AD severity, as well as associations 
between FLG null mutations and AD co‐morbidities.2,6,7 A direct asso‐
ciation between (clinically measured) NMF and AD disease severity and 
co‐morbidities has, to our knowledge, not been demonstrated before.
This study supports the hypothesis that patients with a decreased 
NMF value might benefit from different treatment regimens than pa‐
tients with normal NMF value. Future research should focus on the 
development and implementation of more personalized therapeutic 
approaches for the different endotypes within the AD population.
The results of the current study did not show an association with 
asthma and allergic rhinitis. The relationship between AD, asthma, and 
FLG mutations is complex. FLG mutations are considered a risk factor 
for asthma, but only in the presence of AD.8 Children must be at least 
6 years old for a diagnosis of asthma. In this study, a limited amount of 
patients was aged above 6 years. Future research on the association 
between NMF and asthma should include a larger population of pa‐
tients >6 years of age.
The noninvasive and rapid measurement of NMF by Raman 
spectroscopy makes the method suitable for use in children of all 
ages. The results of the NMF measurements are directly available 
TA B L E  1   Associations of NMF with clinical parameters
Clinical parameters
Decreased NMFa 
(n = 67) Normal NMFa (n = 140)
Decreased NMFb
Odds ratio (95% CI) 
Unadjusted
Odds ratio (95% CI) 
Adjustedc
Onset	of	AD	≤6	months
No 13 42 Reference Reference
Yes 51 93 1.77 (0.87‐3.60) 1.81 (0.89‐3.70)
Disease severity of AD
Mild and moderate 44 113 Reference Reference
Severe 23 27 2.19 (1.14‐4.22) 2.12 (1.02‐4.43)
Allergic sensitization, food
No 31 94 Reference Reference
Yes 36 46 2.37 (1.31‐4.31) 2.27 (1.21‐4.23)
Allergic sensitization, inhalant
No 27 85 Reference Reference
Yes 40 55 2.29 (1.26‐4.15) 2.22 (1.13‐4.34)
Food allergy
No 47 122 Reference Reference
Yes 20 18 2.88 (1.40‐5.93) 2.79 (1.33‐5.86)
Asthma
No 47 116 Reference Reference
Yes 20 24 2.06 (1.04‐4.07) 1.93 (0.92‐4.09)
BHR
No 57 127 Reference Reference
Yes 10 13 1.71 (0.71‐4.14) 1.85 (0.74‐4.64)
Asthma and/or BHR
No 42 104 Reference Reference
Yes 25 36 1.72 (0.92‐3.21) 1.69 (0.85‐3.06)
Allergic rhinitis
No 32 83 Reference Reference
Yes 35 57 1.59 (0.8‐2.86) 1.40 (0.71‐2.73)
Abbreviation: CI, confidence interval.
aValues are based on absolute numbers 
bValues are unadjusted odds ratios (95% confidence interval) from logistic regression models based on observed data. Bold values indicate statistical 
significance at α = 0.05 level. 
cAdjusted for age during measurement and gender. 
Bold values indicate statistical significance at α=0.05 level. 
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and therefore enable to act upon the result without delay. These 
characteristics as well as similar associations with AD as the widely 
replicated associations between FLG null mutations and AD make 
noninvasive measurement of NMF by Raman spectroscopy a prom‐
ising approach to improve clinical stratification of endotypes in AD.
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